MA40065A - N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson - Google Patents

N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson

Info

Publication number: MA40065A
Authority: MA; Morocco
Prior art keywords: parkinson; bis; disease; treatment; mercaptoethyl isophthalamide
Prior art date: 2014-05-30

Application number

MA040065A

Other languages

English (en)

Other versions

MA40065B1 (fr

Inventor

Boyd Eugene Haley

Ragnar Axel Theodor Klingberg

Original Assignee

Emeramed Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-30

Filing date

2015-05-29

Publication date

2021-05-19

2015-05-29 Application filed by Emeramed Ltd filed Critical Emeramed Ltd

2021-05-19 Publication of MA40065A publication Critical patent/MA40065A/fr

2021-09-30 Publication of MA40065B1 publication Critical patent/MA40065B1/fr

Links

208000018737 Parkinson disease Diseases 0.000 title 1
QZUPTXGVPYNUIT-UHFFFAOYSA-N isophthalamide Chemical compound NC(=O)C1=CC=CC(C(N)=O)=C1 QZUPTXGVPYNUIT-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA40065A 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson MA40065B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB1409662.2A GB2526623A (en)	2014-05-30	2014-05-30	New pharmaceutical use
PCT/GB2015/051572 WO2015181567A1 (fr)	2014-05-30	2015-05-29	N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de maladies neurodégénératives

Publications (2)

Publication Number	Publication Date
MA40065A true MA40065A (fr)	2021-05-19
MA40065B1 MA40065B1 (fr)	2021-09-30

Family

ID=51214502

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA40065A MA40065B1 (fr)	2014-05-30	2015-05-29	N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
MA54630A MA54630B1 (fr)	2014-05-30	2020-02-06	N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA54630A MA54630B1 (fr)	2014-05-30	2020-02-06	N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Country Status (17)

Country	Link
US (4)	US20170202791A1 (fr)
EP (2)	EP3903774B1 (fr)
CY (1)	CY1124509T1 (fr)
DK (2)	DK3903774T3 (fr)
ES (2)	ES2938080T3 (fr)
FI (1)	FI3903774T3 (fr)
GB (1)	GB2526623A (fr)
HR (2)	HRP20230105T1 (fr)
HU (2)	HUE055575T2 (fr)
LT (2)	LT3148588T (fr)
MA (2)	MA40065B1 (fr)
PL (2)	PL3903774T3 (fr)
PT (2)	PT3903774T (fr)
RS (2)	RS62095B1 (fr)
SI (2)	SI3148588T1 (fr)
SM (2)	SMT202300015T1 (fr)
WO (1)	WO2015181567A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB202005057D0 (en)	2020-04-06	2020-05-20	Emeramed Ltd	New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6586600B2 (en)	2000-12-06	2003-07-01	University Of Kentucky Research Foundation	Multidentate sulfur-containing ligands
US8349359B2 (en) *	2004-11-07	2013-01-08	Your Energy Systems, LLC	Liposomal formulation for oral administration of glutathione (reduced)
US8950583B2 (en)	2008-12-06	2015-02-10	Ermes Medical Company Limited	Method to remove heavy metals from a mammal
US8575218B2 (en)	2009-09-28	2013-11-05	The University Of Kentucky Research Foundation	Thiol-containing compounds for the removal of elements from tissues and formulations therefor
CA2775397A1 (fr)	2009-09-28	2011-03-31	University Of Kentucky Research Foundation	Composes contenant un thiol pour l'elimination d'elements de milieux contamines et procedes d'utilisation associes
US20110237776A1 (en)	2010-03-25	2011-09-29	Haley Boyd E	Aromatic compounds with sulfur containing ligands
US8426368B2 (en)	2010-03-25	2013-04-23	The University Of Kentucky Research Foundation	Method of ameliorating oxidative stress and supplementing the diet

2014
- 2014-05-30 GB GB1409662.2A patent/GB2526623A/en not_active Withdrawn
2015
- 2015-05-29 LT LTEPPCT/GB2015/051572T patent/LT3148588T/lt unknown
- 2015-05-29 FI FIEP21180847.2T patent/FI3903774T3/fi active
- 2015-05-29 PT PT211808472T patent/PT3903774T/pt unknown
- 2015-05-29 PT PT157338609T patent/PT3148588T/pt unknown
- 2015-05-29 HR HRP20230105TT patent/HRP20230105T1/hr unknown
- 2015-05-29 EP EP21180847.2A patent/EP3903774B1/fr active Active
- 2015-05-29 RS RS20210852A patent/RS62095B1/sr unknown
- 2015-05-29 ES ES21180847T patent/ES2938080T3/es active Active
- 2015-05-29 DK DK21180847.2T patent/DK3903774T3/da active
- 2015-05-29 SM SM20230015T patent/SMT202300015T1/it unknown
- 2015-05-29 LT LTEP21180847.2T patent/LT3903774T/lt unknown
- 2015-05-29 PL PL21180847.2T patent/PL3903774T3/pl unknown
- 2015-05-29 US US15/313,877 patent/US20170202791A1/en not_active Abandoned
- 2015-05-29 PL PL15733860T patent/PL3148588T3/pl unknown
- 2015-05-29 WO PCT/GB2015/051572 patent/WO2015181567A1/fr not_active Ceased
- 2015-05-29 SM SM20210453T patent/SMT202100453T1/it unknown
- 2015-05-29 DK DK15733860.9T patent/DK3148588T3/da active
- 2015-05-29 HU HUE15733860A patent/HUE055575T2/hu unknown
- 2015-05-29 MA MA40065A patent/MA40065B1/fr unknown
- 2015-05-29 SI SI201531710T patent/SI3148588T1/sl unknown
- 2015-05-29 EP EP15733860.9A patent/EP3148588B1/fr active Active
- 2015-05-29 ES ES15733860T patent/ES2882977T3/es active Active
- 2015-05-29 SI SI201531911T patent/SI3903774T1/sl unknown
- 2015-05-29 RS RS20221189A patent/RS63859B1/sr unknown
- 2015-05-29 HU HUE21180847A patent/HUE060927T2/hu unknown
- 2015-05-29 HR HRP20211309TT patent/HRP20211309T1/hr unknown
2017
- 2017-11-22 US US15/821,371 patent/US20180250247A1/en not_active Abandoned
2020
- 2020-02-06 MA MA54630A patent/MA54630B1/fr unknown
2021
- 2021-09-07 CY CY20211100788T patent/CY1124509T1/el unknown
- 2021-12-22 US US17/558,975 patent/US12128017B2/en active Active
2022
- 2022-09-27 US US17/953,622 patent/US11628151B2/en active Active

Also Published As

Publication number	Publication date
PT3903774T (pt)	2022-12-23
LT3903774T (lt)	2023-01-10
ES2938080T3 (es)	2023-04-04
RS62095B1 (sr)	2021-08-31
SI3148588T1 (sl)	2022-01-31
HRP20230105T1 (hr)	2023-03-17
DK3903774T3 (da)	2023-01-16
DK3148588T3 (en)	2021-07-26
LT3148588T (lt)	2021-08-10
RS63859B1 (sr)	2023-01-31
EP3148588A1 (fr)	2017-04-05
US11628151B2 (en)	2023-04-18
GB201409662D0 (en)	2014-07-16
SI3903774T1 (sl)	2023-03-31
US20180250247A1 (en)	2018-09-06
US20220287994A1 (en)	2022-09-15
PT3148588T (pt)	2021-07-15
PL3148588T3 (pl)	2021-12-13
EP3903774B1 (fr)	2022-11-09
HRP20211309T1 (hr)	2021-11-26
US12128017B2 (en)	2024-10-29
WO2015181567A1 (fr)	2015-12-03
US20230013704A1 (en)	2023-01-19
EP3903774A1 (fr)	2021-11-03
FI3903774T3 (fi)	2023-04-12
SMT202100453T1 (it)	2021-09-14
GB2526623A (en)	2015-12-02
HUE060927T2 (hu)	2023-04-28
PL3903774T3 (pl)	2023-03-13
MA54630B1 (fr)	2023-01-31
CY1124509T1 (el)	2022-07-22
MA54630A (fr)	2021-11-03
ES2882977T3 (es)	2021-12-03
EP3148588B1 (fr)	2021-06-23
SMT202300015T1 (it)	2023-03-17
MA40065B1 (fr)	2021-09-30
HUE055575T2 (hu)	2021-12-28
US20170202791A1 (en)	2017-07-20

Publication	Publication Date	Title
IL285722A (en)	2021-09-30	Methods for treating alzheimer's disease
MA49402A (fr)	2020-04-22	Polynucléotides aadc pour le traitement de la maladie de parkinson
IL265206A (en)	2019-05-30	Antisense oligonucleotides for the treatment of eye disease
IL256175A (en)	2018-02-28	Using exosomes to treat the disease
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
IL247085A0 (en)	2016-09-29	Methods for treating Alzheimer's disease
MA52906A (fr)	2021-04-21	Procédé de préparation d'amg 416
IL246999B (en)	2020-09-30	Methods for treating Alzheimer's disease
IL263188B (en)	2021-08-31	Treatment for Parkinson's disease
MA53568A (fr)	2022-02-23	Médicaments pour le traitement de maladies ophtalmiques
EP2959903A4 (fr)	2016-08-03	Médicament pour le traitement de maladie des yeux
HUE060517T2 (hu)	2023-03-28	Immunhiányos betegség kezelésére szolgáló eljárások
LT3413870T (lt)	2021-11-10	Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
EP3354284A4 (fr)	2019-04-10	Composition pour le traitement de la douleur
EP3395350A4 (fr)	2019-09-18	Médicament pour le traitement des infarctus cérébraux
EP3310310A4 (fr)	2019-01-23	Appareil pour le traitement de la maladie de ménière
MA40065A (fr)	2021-05-19	N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
FR3031112B1 (fr)	2018-05-25	Construction d'adn pour le traitement de pathologies oculaires
IL260009B (en)	2021-06-30	Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
IL263837A (en)	2019-02-03	Treatment of ocular disease
EP3344239A4 (fr)	2019-05-22	Compositions et méthodes pour le traitement de la maladie de parkinson
ZA201807944B (en)	2022-06-29	Treatment for parkinson's disease
EP3664788C0 (fr)	2023-06-07	Composés pour le traitement de la maladie de von-hippel-lindau
MA45177A (fr)	2019-04-10	Traitement de la maladie de parkinson
GB201518052D0 (en)	2015-11-25	Parkinson's disease treatment